GLP-1 weight-loss drugs slow biological aging, recent studies show
NewsNation, citing MIT Technology Review, reports that Novo Nordisk and Eli Lilly presented conference findings suggesting overweight or diabetic patients on their GLP-1 drugs had lower biological age on "aging clocks" than placebo. Novo said semaglutide slowed measured aging by about 2 to 3 years in blood samples from more than 10,000 people. Lilly reported similar tirzepatide results. Effects in healthy people remain unclear, and results varied by clock.
Why it matters: Relevant to Maryland adults with overweight or diabetes who are weighing GLP-1 medication, and to clinicians who prescribe or refer for medical weight loss.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to yahoo.com. October 12, 2026.
